312 related articles for article (PubMed ID: 17915849)
1. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
2. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Tintori C; Tuccinardi T; Vincenzi F; Borea PA; Varani K
J Med Chem; 2013 Jun; 56(11):4482-96. PubMed ID: 23697626
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
[TBL] [Abstract][Full Text] [Related]
6. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
Pasquini S; Mugnaini C; Ligresti A; Tafi A; Brogi S; Falciani C; Pedani V; Pesco N; Guida F; Luongo L; Varani K; Borea PA; Maione S; Di Marzo V; Corelli F
J Med Chem; 2012 Jun; 55(11):5391-402. PubMed ID: 22548457
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
Reux B; Nevalainen T; Raitio KH; Koskinen AM
Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
[TBL] [Abstract][Full Text] [Related]
10. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
[TBL] [Abstract][Full Text] [Related]
11. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
Pasquini S; Ligresti A; Mugnaini C; Semeraro T; Cicione L; De Rosa M; Guida F; Luongo L; De Chiaro M; Cascio MG; Bolognini D; Marini P; Pertwee R; Maione S; Di Marzo V; Corelli F
J Med Chem; 2010 Aug; 53(16):5915-28. PubMed ID: 20718492
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
14. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.
Lavey BJ; Kozlowski JA; Hipkin RW; Gonsiorek W; Lundell DJ; Piwinski JJ; Narula S; Lunn CA
Bioorg Med Chem Lett; 2005 Feb; 15(3):783-6. PubMed ID: 15664857
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
Govaerts SJ; Hermans E; Lambert DM
Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
[TBL] [Abstract][Full Text] [Related]
16. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.
Manera C; Saccomanni G; Malfitano AM; Bertini S; Castelli F; Laezza C; Ligresti A; Lucchesi V; Tuccinardi T; Rizzolio F; Bifulco M; Di Marzo V; Giordano A; Macchia M; Martinelli A
Eur J Med Chem; 2012 Jun; 52():284-94. PubMed ID: 22483967
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
19. New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
Manera C; Malfitano AM; Parkkari T; Lucchesi V; Carpi S; Fogli S; Bertini S; Laezza C; Ligresti A; Saccomanni G; Savinainen JR; Ciaglia E; Pisanti S; Gazzerro P; Di Marzo V; Nieri P; Macchia M; Bifulco M
Eur J Med Chem; 2015 Jun; 97():10-8. PubMed ID: 25935384
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]